SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 70 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $230,000 | +411.1% | 238,714 | +527.7% | 0.00% | – |
| Q1 2022 | $45,000 | -96.6% | 38,028 | -90.7% | 0.00% | – |
| Q4 2021 | $1,338,000 | -3.0% | 410,642 | +33.0% | 0.00% | – |
| Q3 2021 | $1,379,000 | -23.0% | 308,653 | -6.2% | 0.00% | – |
| Q2 2021 | $1,792,000 | -5.0% | 328,911 | +30.3% | 0.00% | – |
| Q1 2021 | $1,887,000 | -60.1% | 252,339 | -42.1% | 0.00% | – |
| Q4 2020 | $4,732,000 | +652.3% | 435,964 | +512.0% | 0.00% | – |
| Q3 2020 | $629,000 | +159.9% | 71,241 | +213.3% | 0.00% | – |
| Q2 2020 | $242,000 | +21.0% | 22,742 | -32.6% | 0.00% | – |
| Q1 2020 | $200,000 | -45.8% | 33,725 | -36.9% | 0.00% | – |
| Q4 2019 | $369,000 | -46.3% | 53,428 | -19.3% | 0.00% | – |
| Q3 2019 | $687,000 | +158.3% | 66,177 | +130.2% | 0.00% | – |
| Q2 2019 | $266,000 | +81.0% | 28,750 | +8.8% | 0.00% | – |
| Q4 2018 | $147,000 | -73.7% | 26,428 | -43.5% | 0.00% | – |
| Q3 2018 | $558,000 | +89.8% | 46,800 | +62.5% | 0.00% | – |
| Q2 2018 | $294,000 | +20.5% | 28,800 | +53.2% | 0.00% | – |
| Q1 2018 | $244,000 | +70.6% | 18,800 | +27.9% | 0.00% | – |
| Q4 2017 | $143,000 | – | 14,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |